Zealand Pharma Surprises with Smaller Loss and Bold $200M Share Buyback
Published on: May 7, 2026, 10:54 a.m. | Source: Devdiscourse
Zealand Pharma exceeded market expectations in Q1 with a reduced operating loss, citing robust obesity drug pipeline progress. The company announced a $200 million share buyback and confirmed its future funding strength, partly due to an anticipated $700 million from Roche by 2026.
